Summit Therapeutics Inc. (SMMT) falls 12% after FDA CRL
Summit Therapeutics Inc. (SMMT) falls sharply after the FDA issued a Complete Response Letter for ivonescimab, its lead oncology drug. The setback follows concerns over survival data from the HARMONi study, pressuring the stock and delaying the company’s U.S. approval timeline.
Summit Therapeutics Inc. (SMMT) fell 12% in extended-hours trading after the FDA issued a Complete Response Letter for ivonescimab, its lead oncology asset. The agency’s decision centered on insufficient evidence of a statistically significant overall survival benefit in the HARMONi study, pushing back the drug’s U.S. approval path and weakening the stock’s near-term investment case.
Summit Therapeutics Inc. (NASDAQ: SMMT) falls 12.01% in extended-hours trading, moving from the prior regular-session close of $14.15 to $12.45 at 7:34 a.m. ET on Nov. 16. The sharp decline follows a major FDA setback for ivonescimab, and regular-session trading will confirm whether the after-hours loss holds.
Key Takeaways
SMMT traded at $12.45 in extended-hours trading, down 12.01% from the previous regular-session close.
The primary catalyst is a Nov. 15 FDA Complete Response Letter for ivonescimab, Summit's lead oncology asset.
The FDA cited insufficient evidence of a statistically significant overall survival benefit in the HARMONi study.
Summit's latest quarterly EPS beat estimates, but the company still lists EPS of -$1.06 and has a $11.29B market cap.
The investment case now depends more heavily on the FDA response, additional clinical evidence, and the timing of a possible U.S. approval.
Why Summit Therapeutics Inc. (SMMT) Is Falling After the FDA CRL
The catalyst is specific and company-driven. On Nov. 15, Summit announced that the FDA issued a Complete Response Letter for its biologics license application covering ivonescimab with platinum-containing chemotherapy. The application targeted patients with locally advanced or metastatic non-small cell lung cancer after prior EGFR TKI therapy. followed a Nov. 14 PDUFA date, placing the decision directly inside the trading window investors had been tracking.
A Complete Response Letter means the FDA did not approve the application in its current form. News coverage tied the decision to the HARMONi study's failure to show a statistically significant overall survival benefit. That distinction matters. The market is reacting to an efficacy concern tied to the main dataset, rather than a routine administrative delay.
Ivonescimab represented Summit's most important near-term U.S. commercial opportunity. Therefore, the FDA action pushes back the potential revenue timeline and lowers the probability-adjusted value of the program. For a development-stage biotech, that is a direct hit to the central equity thesis.
How SMMT Earnings and Valuation Frame the Biotech Selloff
The latest earnings result does not explain the decline. Summit reported EPS of -$0.26 on Nov. 4 against an estimate of -$0.28, producing a 7.1% positive surprise. However, the company's earnings history shows just 2 beats across the last 8 quarters. The FDA decision, rather than the latest EPS result, is the material event behind this move.
Summit's fundamentals still show a loss-making development business. The stock data lists EPS at -$1.06, while the company carries an $11.29B market capitalization. That valuation places heavy weight on future product approval and commercial execution. When the FDA challenges the lead filing, the market has little current earnings power to cushion the repricing.
Price history adds perspective. SMMT's 52-week range runs from $12.07 to $29.23, and the extended-hours print of $12.45 sits close to the low end of that range. A Nov. 10 market report also noted that the shares had closed at $17.84 after roughly a sevenfold three-year run. That earlier momentum helps explain why a binary regulatory setback produced such a fast reversal.
Ivonescimab Pipeline and Summit Therapeutics' Competitive Position
Ivonescimab is a bispecific antibody designed to combine PD-1 blockade with an anti-angiogenesis mechanism. Summit is developing the drug for non-small cell lung cancer and colorectal cancer, and the company has also studied combinations with chemotherapy in Phase III programs.
That pipeline gives Summit more than one clinical program, but the rejected NSCLC application carried the clearest near-term commercial importance. The FDA's survival concern weakens the competitive narrative until Summit addresses the evidence behind the HARMONi result. In oncology, a promising mechanism matters less when the pivotal survival data fail to satisfy regulators.
The stock's previous analyst support also deserves careful treatment. Citizens reiterated a Market Outperform rating with a $40 target on Oct. 27, while the analyst consensus listed 15 Buy ratings, 8 Holds, and zero Sell ratings. Those opinions came before or around the regulatory event and do not provide a reliable floor after a CRL. A regulatory setback can make older targets stale in a single session, which is one of biotech's less charming traditions.
What SMMT Investors Should Do After the After-Hours Drop
Investors should first separate the FDA event from the earnings story. The Nov. 4 EPS beat offers limited protection because Summit remains loss-making and the regulatory decision affects the company's lead asset. A lower share price alone does not repair the clinical evidence issue.
Second, position size matters. The $12.07 52-week low and the $14.15 prior close provide clear reference points for judging price action, but neither level confirms value. The stock can stabilize near those prices only if buyers accept the revised approval risk, not simply because the shares have fallen.
Third, focus on the regulatory remedy. The relevant investment test is whether Summit can address the FDA's concerns with additional analyses, clinical evidence, or other requested information and establish a credible path for the ivonescimab application. Until that path becomes concrete, SMMT remains an event-driven biotech rather than a conventional earnings compounder.
Finally, avoid treating old price targets as a valuation anchor. The $33.13 consensus target was built before the CRL and reflects a different probability of U.S. approval. A disciplined approach gives greater weight to the FDA decision and the company's response than to analyst targets published before the setback.
Bottom Line for Summit Therapeutics Inc. Investors
SMMT falls because the FDA rejected the current ivonescimab application after the HARMONi study failed to show a statistically significant overall survival benefit. The negative EPS profile and $11.29B market cap amplify the impact because investors valued Summit mainly on future approval and commercialization potential. The after-hours decline is a sharp reset of that expectation, and regular-session price action will show whether the market accepts the new risk level.
SMMT is down because the FDA issued a Complete Response Letter for ivonescimab, Summit’s lead drug candidate. The agency cited insufficient evidence of a statistically significant overall survival benefit, which hurt the stock’s approval outlook.
+Should I buy SMMT stock now?
Not on this news alone. The FDA setback materially raises approval risk, so investors should wait for clearer evidence that Summit can address the agency’s concerns before treating the drop as a buying opportunity.
+What does the FDA Complete Response Letter mean for Summit Therapeutics?
A Complete Response Letter means the FDA did not approve the application in its current form. Summit will need to provide more data or additional analysis before ivonescimab can move forward in the U.S. approval process.
+Is the earnings report the reason SMMT fell?
No, the earnings report is not the main driver of the decline. The stock is falling because of the FDA decision on ivonescimab, which is far more important to Summit’s valuation than its latest EPS result.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on SMMT?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.